Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities towards the market (RNAi, modified mRNA, single domain antibodies) and in helping build several multi-billion dollar companies from start-up stage. Prior to joining Evox, Tony … Read more
Dr. Per Lundin is Co-Founder & Chief Business Officer of Evox Therapeutics Ltd. He has ~15 years’ experience founding, leading and advising biotech companies developing advanced therapies. Prior to co-founding and building out Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing allogeneic cell therapies for autoimmune and inflammatory diseases, and ultimately … Read more
Sonya’s extensive experience in early development includes a focus on translational medicine, leading programmes in gene therapy, biologics, including antisense RNA, and small molecules. She has led successful interactions with health authorities globally, supporting IND/CTA, first-in-class NMEs, and negotiation of a SPA leading to NDA and MAA. Prior to joining Evox, Sonya was most recently … Read more
Kerry is a strategic and commercially-focused leader with significant experience in business change and transformation. Motivated by a passion to drive the culture and ethos of a company, as Head of HR at Centrica Customer Services she enabled the organisation to effectively engage with both their employees and with key audiences. With the ability to influence … Read more
Peter has more than 30 years of process development experience in the biopharmaceutical industry, including cell and gene therapies. During those years, he was involved in bringing more than 16 products to commercialization. Before joining Evox, he was Executive Director, Process Development at Autolus Therapeutics, where he led late-stage CMC activities for the AUTO1 (obe-cel) … Read more
David’s extensive experience at Astra Zeneca includes having accountability for the isolation and optimisation of antibodies, proteins, and peptides for therapeutic development. He and his team delivered lead molecules for the Respiratory, Inflammatory, and Autoimmunity antibody projects. David was the Global Head of In Vivo Expressed Biologics at AZ focusing on exploring and advancing new … Read more